Molbank (Jan 2023)

3-(3,4-Dichlorophenyl)-5-(1<i>H</i>-indol-5-yl)-1,2,4-oxadiazole

  • Julia A. Efimova,
  • Anton A. Shetnev,
  • Sergey V. Baykov,
  • Anél Petzer,
  • Jacobus P. Petzer

DOI
https://doi.org/10.3390/M1552
Journal volume & issue
Vol. 2023, no. 1
p. M1552

Abstract

Read online

3-(3,4-Dichlorophenyl)-5-(1H-indol-5-yl)-1,2,4-oxadiazole was synthesized via the condensation of 3,4-dichlorobenzamidoxime and methyl 1H-indole-5-carboxylate using a superbasic medium (NaOH/DMSO). The compound was tested as a potential inhibitor of human monoamine oxidase (MAO) A and B. It demonstrated a notable inhibition with an IC50 value of 0.036 μM for the MAO-B and isoform specificity. The product was characterized by 1H-NMR, 13C-NMR, and HRMS. In conclusion, the new active MAO-B inhibitor may serve as a candidate for the future discovery of therapeutic agents for neurodegenerative disorders such as Parkinson’s disease.

Keywords